INM SEC Filings
SEC filings for INM. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 4Schneeberger Daniel | Oct 16, 2026 | 0001940272-26-000025EDGAR |
| 4Schneeberger Daniel | Oct 9, 2026 | 0001940272-26-000023EDGAR |
| SC 13G/AamendedDaniel Schneeberger and 1 other reporting person | Oct 8, 2026 | 0001104659-26-114415EDGAR |
| 4Schneeberger Daniel | Oct 6, 2026 | 0001940272-26-000022EDGAR |
| 8-K | Sep 19, 2026 | 0001213900-26-101492EDGAR |
| 4Schneeberger Daniel | Sep 17, 2026 | 0001940272-26-000021EDGAR |
| 10-K | Sep 10, 2026 | 0001213900-26-098419EDGAR |
| SC 13GIkarian Capital, LLC and 1 other reporting person | Aug 15, 2026 | 0001193125-26-352958EDGAR |
| 8-K | Jul 23, 2026 | 0001213900-26-080414EDGAR |
| 4Schneeberger Daniel | Jul 18, 2026 | 0001940272-26-000010EDGAR |
| 4Vivo Opportunity Cayman Fund, L.P. | Jul 17, 2026 | 0001213900-26-078891EDGAR |
| 8-KAIOn July 6, 2026, InMed Pharmaceuticals and Mentari Therapeutics signed Amendment No. 1 to their May 19, 2026 all-stock merger agreement. | Jul 11, 2026 | 0001213900-26-077127EDGAR |
| 4Vivo Opportunity Cayman Fund, L.P. | Jul 3, 2026 | 0001213900-26-075144EDGAR |
| SC 13DVivo Opportunity Fund Holdings, L.P. and 3 other reporting persons | Jun 11, 2026 | 0001213900-26-067514EDGAR |
| 4Vivo Opportunity Cayman Fund, L.P. | Jun 11, 2026 | 0001213900-26-067505EDGAR |
| 8-K | Jun 10, 2026 | 0001062993-26-003132EDGAR |
| SC 13GADAR1 Capital Management, LLC and 1 other reporting person | Jun 6, 2026 | 0001104659-26-071020EDGAR |
| SC 13GSquadron Capital Management LLC and 3 other reporting persons | May 28, 2026 | 0002050709-26-000019EDGAR |
| 4Schneeberger Daniel | May 22, 2026 | 0001940272-26-000008EDGAR |
| 8-K | May 19, 2026 | 0001062993-26-002787EDGAR |
| 8-K | May 19, 2026 | 0001213900-26-058795EDGAR |
| 8-K | May 7, 2026 | 0001062993-26-002371EDGAR |
| 10-QAIInMed's MD&A is dominated by distress signals: a going concern warning, a Nasdaq minimum bid price deficiency, the wind-down of its only revenue-generating segment, and widening net losses. | May 7, 2026 | 0001213900-26-052920EDGAR |
| 8-K | Apr 28, 2026 | 0001213900-26-048064EDGAR |
| 8-K | Apr 4, 2026 | 0001213900-26-039943EDGAR |
| 8-K | Mar 31, 2026 | 0001062993-26-001697EDGAR |
| 8-K | Mar 23, 2026 | 0001062993-26-001567EDGAR |
| 8-KAIInMed Pharmaceuticals furnished a 2026 pharmaceutical development outlook under Regulation FD. | Mar 9, 2026 | 0001062993-26-001347EDGAR |
| 8-KAIOn March 4, 2026, InMed Pharmaceuticals' board approved the wind down and exit of BayMedica LLC's commercial operations, the company's only revenue-generating business, because H.R. | Mar 7, 2026 | 0001213900-26-024752EDGAR |
| 8-K | Feb 12, 2026 | 0001062993-26-000819EDGAR |
| 10-Q | Feb 12, 2026 | 0001213900-26-014996EDGAR |
| SC 13GSABBY MANAGEMENT, LLC and 2 other reporting persons | Jan 21, 2026 | 0001535610-26-000009EDGAR |
| 8-K | Dec 18, 2025 | 0001062993-25-017390EDGAR |
| 8-KAIInMed Pharmaceuticals disclosed on December 12, 2025 that H.R. | Dec 15, 2025 | 0001213900-25-121497EDGAR |
| 8-KAIOn November 18, 2025, InMed Pharmaceuticals announced successful completion of its first large animal pharmacokinetic studies of the oral formulation of INM-901, its Alzheimer's disease candidate. | Nov 20, 2025 | 0001213900-25-112644EDGAR |
| 10-QAIA pre-revenue-stage pharma filing dominated by going-concern doubt, continuing losses, a funding gap and a declining commercial segment. | Nov 7, 2025 | 0001213900-25-107152EDGAR |
| 10-K/Aamended | Oct 25, 2025 | 0001213900-25-102157EDGAR |
| 8-K | Oct 17, 2025 | 0001213900-25-099529EDGAR |
Never miss a INM filing.
Get an email when INM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.